The population is ageing at an accelerating pace, bringing dual technical and commercial challenges to the early screening of neurodegenerative diseases.
As multiple innovative therapies for Alzheimer’s Disease become available, market demand for convenient, accurate early screening solutions is surging. Ultra-sensitive blood biomarker testing technologies are maturing, yet translating lab-validated assays into widespread clinical adoption requires overcoming multiple hurdles, including medical insurance coverage, clinical consensus-building and the development of a commercial ecosystem.
Faced with substantial unmet clinical needs alongside the barriers to rolling out early screening products, real-world industry insights will be shared at the Hongqiao International Science and Technology Week 2026 forum.
Hongqiao International Science and Technology Week 2026 will be held at the National Exhibition and Convention Center (Shanghai) from November 20 to 22. As one of its six thematic stages, the Life Science & Healthcare Stage brings together industry practitioners in life sciences, innovative drug R&D and health technology. Keynote speeches and discussions will be held to explore cutting-edge technological breakthroughs and industrial innovation trends.
Its agenda covers innovative drug R&D, cell and gene therapy, translation of life science achievements and health industry development. It focuses on integrating research innovation and industrial adoption to accelerate technological advances and commercialisation in life sciences.
At this forum, Jiemin Yan, CEO of AstraBio, will deliver the keynote speech The Era of Innovative Therapies: Translating Alzheimer’s Early Screening from Technical Breakthroughs to Commercial Launch. Drawing on years of commercial management experience in life sciences, she will share practical pathways for moving cutting-edge Alzheimer’s early screening technologies from R&D to market and integrating them into the industrial ecosystem.
Keynote The Era of Innovative Therapies: Translating Alzheimer’s Early Screening from Technical Breakthroughs to Commercial Launch
As the social and health-economic burdens brought by population ageing keep rising, there is an increasingly urgent demand for integrated screening, diagnosis and treatment solutions for neurological disorders such as Alzheimer’s disease. How to realise a viable route for new technologies from lab to commercialisation, and embed them effectively into the new industrial value chain, is a core challenge for every innovative enterprise.
Speech Date: November 21, 2026 Stage: Life Science & Healthcare
Speaker Bio
emin Yan AstraBio CEO
Jiemin Yan has over 20 years of experience in business development and management. She previously held roles including Business Director for Life Sciences China at PerkinElmer, Vice President and General Manager of Greater China at MD, a Danaher Group company, and General Manager, Asia-Pacific at Quanterix.
After earning her MBA in 2016, she has led teams to advance local innovation. She has delivered rapid business growth, built teams and driven domestic innovation across fundamental research, clinical translation and in vitro diagnostics (IVD). She now leads AstraBio to advance the clinical translation of biomarkers, with a focus on the clinical deployment of ultra-sensitive blood assays for pan-neurological biomarkers.
Register to visit.
